STOCK TITAN

Shattuck Labs (STTK) Stock Price, News & Analysis

STTK NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
64 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+20.6% close of January 7, 2026
1-year change
+131.8% closing prices, November 17, 2025 to November 17, 2026
1-month change
-15.3% closing prices, October 16, 2026 to November 17, 2026

Company Description

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company focused on the development of potential treatments for autoimmune, inflammatory, and other immune‑mediated diseases. The company describes itself as pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors, with a particular emphasis on the Death Receptor 3 (DR3)/TL1A pathway that has been clinically validated in inflammatory bowel disease (IBD).

According to Shattuck, its work centers on protein engineering and the creation of TNF receptor agonist and antagonist therapeutics. This expertise is reflected in its lead program, SL‑325, which the company characterizes as a potentially first‑in‑class DR3 antagonist (blocking) antibody. SL‑325 is designed to achieve a complete and durable blockade of the DR3/TL1A pathway, which Shattuck views as a key mechanism in IBD and other inflammatory and immune‑mediated or autoimmune diseases.

Core Program: SL‑325 and the DR3/TL1A Pathway

Shattuck reports that SL‑325 is a fully Fc‑silenced humanized immunoglobulin G monoclonal antibody. In preclinical studies described by the company, SL‑325 demonstrated high‑affinity binding to human DR3 and potent inhibition of TL1A binding to DR3. Shattuck also notes a favorable safety profile in non‑human primate studies and indicates that SL‑325 has been evaluated in GLP toxicology studies.

The company states that SL‑325 is being developed as a potential treatment for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis as referenced in its private placement announcement, as well as other inflammatory and immune‑mediated or autoimmune diseases. Shattuck highlights that SL‑325 is intended to provide a more complete blockade of the DR3/TL1A pathway than approaches that target TL1A alone.

In multiple press releases, Shattuck describes SL‑325 as the first DR3 blocking antibody to enter clinical development and notes that it is being studied in a Phase 1 clinical trial in healthy volunteers. The Phase 1 trial is described as assessing safety, tolerability, immunogenicity, and pharmacokinetics, and is intended to determine a recommended Phase 2 dose and dosing schedule.

Scientific Rationale and Preclinical Insights

Shattuck’s communications emphasize a data‑driven rationale for targeting DR3 rather than its ligand, TL1A. The company reports that preclinical studies of SL‑325 show high‑affinity binding and superior activity over TL1A antibodies. It further notes that targeting the TNF receptor DR3, instead of TL1A, may avoid immune complex formation and stabilization of TL1A, which Shattuck suggests could influence immunogenicity profiles.

In preclinical work presented by the company, SL‑325 is described as having no evidence of residual agonism, full receptor occupancy at certain dose levels in non‑human primates, and durable receptor occupancy over several weeks. Shattuck also notes that no infusion‑related reactions were observed in those non‑human primate studies and that clinical pathology, gross pathology, and histopathology assessments were favorable at the evaluated doses.

Pipeline Beyond the Lead Candidate

Beyond SL‑325, Shattuck states that it is advancing multiple preclinical DR3‑based bispecific antibodies. These candidates are described as being designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with IBD. The company has indicated in several press releases that it continues to make progress in preclinical development of these bispecific antibodies and has discussed plans to nominate a lead bispecific candidate from its preclinical pipeline.

Shattuck has also referenced SL‑425 in prior descriptions as a half‑life extended version of SL‑325 and has mentioned multiple other preclinical DR3‑based bispecific antibodies in the context of IBD and related inflammatory conditions. These programs are positioned by the company as extensions of its DR3‑focused platform and its broader work in TNF receptor therapeutics.

Clinical‑Stage Status and Regulatory Milestones

Shattuck characterizes itself as a clinical‑stage biotechnology company. The company has announced the submission and effect of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for SL‑325 for the treatment of IBD. It has also reported the dosing of the first participants in a Phase 1 clinical trial of SL‑325 in healthy volunteers and has described the trial as including single‑ascending dose (SAD) and multiple‑ascending dose (MAD) components.

In its public updates, Shattuck links these clinical milestones to its strategy of generating data to support SL‑325 as a potentially first‑in‑class DR3 blocking antibody. The company’s disclosures also connect its clinical plans with its financing activities, noting that proceeds from private placements are expected to support advancement of SL‑325 through Phase 1 and into planned Phase 2 trials in IBD and potentially other autoimmune or inflammatory diseases.

Corporate and Capital Markets Profile

Shattuck Labs, Inc. is incorporated in Delaware and lists its common stock on The Nasdaq Global Select Market under the ticker symbol STTK, as confirmed in multiple Form 8‑K filings. Those filings also identify the company’s principal executive offices as being located in Austin, Texas, and the company states in its press releases that it has offices in both Austin, Texas and Durham, North Carolina.

The company has used private placements and other equity financings to support its research and development programs. For example, Shattuck has announced a private placement of up to approximately $103 million in gross proceeds, led by institutional investors, with associated common stock and warrant structures. The company has also disclosed inducement equity awards granted under Nasdaq Listing Rule 5635(c)(4) in connection with new hires, reflecting its use of equity‑based compensation as part of its employment and governance practices.

Focus on Autoimmune and Inflammatory Diseases

Across its press releases, Shattuck consistently describes its therapeutic focus as autoimmune/inflammatory diseases and inflammatory and immune‑mediated diseases. Within this broad category, IBD is highlighted as a primary indication for SL‑325, with the company also referencing other inflammatory autoimmune diseases and autoimmune or inflammatory conditions as potential areas of interest.

The company’s participation in scientific and medical conferences, such as meetings focused on gastroenterology, inflammatory bowel disease, and immunology, aligns with this stated focus. Shattuck has reported presentations of preclinical data for SL‑325 at conferences including those organized by IBD‑focused foundations and professional societies, as well as investor‑oriented healthcare conferences where it discusses its development plans and scientific rationale.

Engagement with the Scientific and Investment Communities

Shattuck’s news releases describe active engagement with both scientific and financial audiences. The company has participated in key opinion leader (KOL) panels on DR3/TL1A biology and IBD, investor conferences hosted by healthcare‑focused banks and research firms, and scientific meetings where it presents preclinical data on SL‑325 and its DR3‑based platform.

Through these activities, Shattuck communicates its development strategy, the mechanistic basis for targeting DR3, and the status of its clinical and preclinical programs. The company also uses periodic financial results announcements, furnished to the U.S. Securities and Exchange Commission (SEC) via Form 8‑K, to summarize its cash position, research and development spending, and expectations about how long its capital resources may support its operations, while noting that such expectations are subject to risks and uncertainties as described in its SEC filings.

Regulatory Filings and Governance

Shattuck Labs files periodic and current reports with the SEC, including Form 8‑K reports that disclose material events such as private placements, changes to the Board of Directors, and financial results. For example, the company has reported the appointment of new directors associated with a significant private placement, as well as the resignations of certain other directors and the resulting changes in board composition.

These filings also confirm the company’s listing status on The Nasdaq Global Select Market and provide details on securities such as common stock, pre‑funded warrants, and common warrants issued in connection with financings. Shattuck’s 8‑K and 8‑K/A filings further indicate that certain financial press releases are furnished, rather than filed, under SEC rules, which has implications for how those disclosures are incorporated into other regulatory documents.

Summary

In summary, Shattuck Labs, Inc. is a Nasdaq‑listed, clinical‑stage biotechnology company that focuses on autoimmune, inflammatory, and immune‑mediated diseases through the lens of TNF superfamily receptor biology. Its lead program, SL‑325, is described as a potentially first‑in‑class DR3 blocking antibody aimed at IBD and related conditions, supported by preclinical data and an ongoing Phase 1 clinical trial in healthy volunteers. The company complements this lead asset with preclinical DR3‑based bispecific antibody programs and uses equity financings and SEC‑registered securities to fund its research and development activities.

Stock Performance

$4.59
-1.50%
-0.07
Last updated: at
+131.8%
Performance 1 year
$467.5M

Shattuck Labs (STTK) closed at $4.59 on November 17, 2026. Over the past 12 months, the price has gained 131.8%.

See what a $1,000 investment in STTK would be worth today

Average down calculator for STTK

STTK Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Shattuck Labs generated $1.0M in revenue in FY2025, operating income reached -$51.5M, and net income was -$48.8M. Diluted earnings per share stood at -$0.70. The company generated -$39.9M in operating cash flow. The current ratio was 11.70, measuring current assets divided by current liabilities.

$1.0M
Revenue (FY2025)
-$48.8M
Net Income (FY2025)
-$39.9M
Operating Cash Flow

Upcoming Events

H1
2027
H1 2027 Clinical

SL-846 Phase 1 start

SL-846 (DR3 x IL-23R) Phase 1 trial start and initial data planned in 2027; GLP tox ongoing, timing subject to change.
YEAR
2027
2027 Clinical

SL-846 Phase 1 data

Initial SL-846 Phase 1 data expected in 2027 from healthy-volunteer study; initial safety/tolerability readouts may drive value.
H1
2028
H1 2028 Clinical

Week 16 results

Topline Week 16 efficacy results from RECEPTIVE-HS1 expected in H1 2028 for SL-325; primary endpoint: ≥50% abscess/nodule reduction.
H1
2028
H1 2028 Clinical

RECEPTIVE-CD1 readout

12-week endoscopic response data from RECEPTIVE-CD1 Phase 2b expected in H1 2028 (Jan 1–Jun 30, 2028); randomized trial ~232 patients.
H1
2028
H1 2028 Clinical

SL-325 Crohn's readout

12-week induction data from SL-325 Phase 2b Crohn's trial expected in H1 2028; pivotal for program progression and valuation.
DEC
10
December 10, 2035 Corporate

Option expiration

Options expire 10 years after grant (Dec 10, 2035); exercise price $3.23

Shattuck Labs has 6 upcoming scheduled events. The next event, "SL-846 Phase 1 start", is expected in H1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the STTK stock price.

Short Interest History

Last 12 Months

Short interest in Shattuck Labs (STTK) currently stands at 10.7 million shares, up 2.9% from the previous reporting period, representing 12.3% of the float. Since November 2025, short interest has increased by 1505.2%.

Days to Cover History

Last 12 Months

Days to cover for Shattuck Labs (STTK) currently stands at 12.0 days, up 65.3% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 108.5%. Across the settlements charted above, it has ranged from 1.4 to 12.0 days.

STTK Company Profile & Sector Positioning

Shattuck Labs (STTK) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing STTK often look at related companies in the same sector, including DiaMedica Therapeutics Inc. (DMAC), Avalo Therapeutics, Inc. (AVTX), Monopar Therapeutics Inc. (MNPR), Assembly Biosciences, Inc (ASMB), and Neurogene, Inc. (NGNE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate STTK's relative position within its industry.

Frequently Asked Questions

The current stock price of Shattuck Labs (STTK) is $4.59 as of November 17, 2026.

The market cap of Shattuck Labs (STTK) is approximately $467.5M. Learn more about what market capitalization means .

The FY2025 revenue of Shattuck Labs (STTK) is $1.0M, from its most recent completed fiscal year.

The FY2025 net income of Shattuck Labs (STTK) is -$48.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Shattuck Labs (STTK) is -$0.70 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Shattuck Labs (STTK) is -$39.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Shattuck Labs (STTK), current assets divided by current liabilities, was 11.70 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Shattuck Labs (STTK) is -$51.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Shattuck Labs, Inc. is a clinical-stage biotechnology company that focuses on developing potential treatments for autoimmune, inflammatory, and other immune-mediated diseases. The company describes its work as pioneering novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors, with a particular emphasis on the DR3/TL1A pathway in inflammatory bowel disease (IBD).

SL-325 is Shattuck Labs’ lead product candidate, which the company describes as a potentially first-in-class Death Receptor 3 (DR3) blocking antibody. It is a fully Fc-silenced humanized immunoglobulin G monoclonal antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway, and is being developed for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated or autoimmune diseases.

Shattuck states that SL-325 is being developed primarily for inflammatory bowel disease (IBD), and has referenced Crohn’s disease and ulcerative colitis in its financing announcements. The company also notes that SL-325 and related programs are intended for other inflammatory and immune-mediated or autoimmune diseases.

According to Shattuck, preclinical studies of SL-325 demonstrate high-affinity binding and superior activity over TL1A antibodies. The company explains that targeting the TNF receptor DR3, rather than its ligand TL1A, offers a data-driven rationale that may avoid immune complex formation and stabilization of TL1A, which it suggests could influence immunogenicity and support development of DR3-based bispecific antibodies.

Shattuck describes itself as a clinical-stage biotechnology company and reports that SL-325 is being evaluated in a Phase 1 clinical trial in healthy volunteers. The trial includes single-ascending dose and multiple-ascending dose components and is designed to assess safety, tolerability, immunogenicity, and pharmacokinetics, as well as to determine a recommended Phase 2 dose and dosing schedule.

Yes. In addition to SL-325, Shattuck reports that it is developing multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease. The company has also referenced SL-425, described as a half-life extended version of SL-325, and other preclinical DR3-based bispecific antibodies.

Shattuck Labs, Inc. lists its common stock on The Nasdaq Global Select Market under the ticker symbol STTK. This listing information is confirmed in the company’s current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Shattuck’s SEC filings identify its principal executive offices in Austin, Texas, and the company states in its press releases that it has offices in both Austin, Texas and Durham, North Carolina. These locations reflect the company’s operational footprint as described in its public disclosures.

Shattuck has disclosed that it uses equity financings, including private placements of common stock and warrants, to fund its operations and development programs. For example, the company announced a private placement of up to approximately $103 million in gross proceeds, led by institutional investors, and has also granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) in connection with new hires.

Shattuck Labs files current reports on Form 8-K to disclose material events such as private placements, changes to its Board of Directors, and the release of quarterly financial results. These filings confirm its Nasdaq listing, describe securities such as common stock and warrants, and often include or reference press releases that provide additional detail on financial and operational updates.